

Press release

Lund, SWEDEN – April 20, 2010

Final outcome of Hansa Medical's rights issue

The final outcome of Hansa Medical's rights issue shows that the rights issue has been oversubscribed by 22,4 % and that 93,8 % of the shares has been subscribed through preferential rights. As a result of the rights issue, Hansa Medical will receive approximately SEK 27 million before issue expenses.

Of the rights issue, 93,8 %, corresponding to 3 622 747 shares, were subscribed for through preferential rights. Subscription of shares without preferential rights were made for 28,6 % of the rights issue, corresponding to 1 105 327 shares. Of these shares, 240 437 shares, corresponding to 6,2 % of the rights issue, have been allotted to persons who have subscribed to shares without preferential rights. A statement will be sent on April 20, 2010 confirming allotment of new shares to those subscribers who subscribed for new shares without the support of subscription rights. Statements will only be sent to subscribers that have been allotted shares.

As a result of the rights issue, the number of Hansa Medical shares will increase by 3 863 184. After the rights issue the share capital amounts to 38 631 840 distributed on 7 726 368 shares. After registration of the increase in share capital at the Swedish Companies Registration Office, the paid subscription shares ("BTAs") in the rights issue will be converted to new shares. New shares are expected to become subject to trading on NASDAQ OMX First North on May 10, 2010.

Rights issue in brief

Hansa Medical's Board of Directors decided March 4, 2010 to implement a new issue of 3,863,184 shares at a price of SEK 7 each. At full subscription, the share issue raises SEK 27 million before issue expenses. Shareholders in Hansa Medical AB had preferential rights to the subscription of new shares and one existing share entitled to subscription of one new share. The share issue was fully secured by Farstorp Invest AB. The subscription period was from March 24 through April 14, 2010.

The reason underlying the new share issue is to secure favourable development of the company's principal projects anti-alpha-11, IdeS and HMD-301. The funds from the rights issue will primarily be allocated to identification of an anti-alpha-11 lead candidate and production of IdeS.

For more information, please contact:

Hansa Medical AB

Emanuel Björne, CEO

Mobile: +46 707 175477

E-mail: emanuel.bjorne@hansamedical.com

Bo Håkansson, Chairman of the board

Mobile: +46 705 98 57 22

E-mail: boh@farstorp.com

ABOUT HANSA MEDICAL

Hansa Medical is a preclinical and early clinical biopharmaceutical development company focused on inflammation. The company develops three product candidates; IdeS, anti-alpha-11 and HMD-301. IdeS is a novel treatment prior to organ transplantation. Anti-alpha-11 is a novel and more specific rheumatoid arthritis treatment. HMD-301 is a novel diagnostic method for diagnosis and prognosis of severe sepsis. Hansa Medical is publicly traded at NASDAQ OMX First North under ticker symbol HMED. Remium AB is Certified Adviser to Hansa Medical.

Hansa Medical AB
P.O. Box 785
SE-220 07 Lund, SWEDEN
TELEFON +46 46 16 56 70
TELEFAX +46 46 12 77 75
info@hansamedical.com
www.hansamedical.com

VISITING ADDRESS:
Scheelevägen 22
Lund, SWEDEN